New York: Biolinerx (NASDAQ:BLRX) Stock Has Just Had Its “Buy” Rating Reiterated by Oppenheimer. Shares now Have a $3.0 Target

September 17, 2017 - By Dolores Ford

 New York: Biolinerx (NASDAQ:BLRX) Stock Has Just Had Its

Biolinerx (NASDAQ:BLRX) Rating Reaffirmed

New York: In analysts report shared with investors and clients on Tuesday, 12 September, Oppenheimer reaffirmed their “Buy” rating on Biolinerx (NASDAQ:BLRX) shares. They now have a $3.0 target on the company. Oppenheimer’s target means a potential upside of 185.71 % from the company’s last price.

Bioline RX Ltd (NASDAQ:BLRX) Ratings Coverage

Among 6 analysts covering BioLineRx (NASDAQ:BLRX), 6 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. BioLineRx has $7 highest and $3.0 lowest target. $3.83’s average target is 264.76% above currents $1.05 stock price. BioLineRx had 14 analyst reports since July 27, 2015 according to SRatingsIntel. The stock has “Market Outperform” rating by JMP Securities on Wednesday, March 9. H.C. Wainwright maintained the shares of BLRX in report on Friday, June 2 with “Buy” rating. The rating was maintained by Maxim Group with “Buy” on Monday, July 10. The stock of Bioline RX Ltd (NASDAQ:BLRX) earned “Hold” rating by Maxim Group on Friday, August 12. The rating was upgraded by Maxim Group to “Buy” on Thursday, May 18. On Monday, July 27 the stock rating was maintained by TH Capital with “Buy”. Maxim Group maintained the shares of BLRX in report on Thursday, June 1 with “Buy” rating. Roth Capital initiated the shares of BLRX in report on Thursday, August 3 with “Buy” rating. The stock of Bioline RX Ltd (NASDAQ:BLRX) has “Buy” rating given on Tuesday, August 8 by Maxim Group. H.C. Wainwright maintained Bioline RX Ltd (NASDAQ:BLRX) on Friday, May 26 with “Buy” rating.

The stock increased 0.96% or $0.01 on September 15, reaching $1.05. About 125,334 shares traded. Bioline RX Ltd (NASDAQ:BLRX) has declined 6.10% since September 17, 2016 and is downtrending. It has underperformed by 22.80% the S&P500.

Analysts expect Bioline RX Ltd (NASDAQ:BLRX) to report $-0.05 EPS on November, 28.They anticipate $0.03 EPS change or 37.50 % from last quarter’s $-0.08 EPS. After having $-0.05 EPS previously, Bioline RX Ltd’s analysts see 0.00 % EPS growth.

BioLine RX Ltd is an Israel-based company engaged in the development of therapeutics, from preclinical-stage development to advanced clinical trials, for a range of medical needs. The company has market cap of $109.32 million. The Company’s clinical therapeutic candidates under development consist of BL-1020 that is in Phase II/III clinical trials to improve cognitive function in schizophrenia patients; BL-1040, which is under pivotal CE-Mark registration trial for the prevention of cardiac remodeling following an acute myocardial infarction; BL-5010, which has completed Phase I/II clinical trials for non-surgical removal of skin lesions; BL-1021 that has completed Phase Ia clinical trial for the treatment of neuropathic pain or pain that results from damage to nerve fibers, and BL-7040, a synthetic oligonucleotide, which is in Phase II clinical trial for the treatment of inflammatory bowel disease. It currently has negative earnings.

More notable recent Bioline RX Ltd (NASDAQ:BLRX) news were published by: Seekingalpha.com which released: “BiolineRx: COMBAT Engagement” on April 19, 2017, also Seekingalpha.com with their article: “Investors Waiting In BioLineRx” published on July 18, 2017, Seekingalpha.com published: “BioLineRx: Why I See Significant Upside Potential In This $1 Biotech Stock” on September 01, 2017. More interesting news about Bioline RX Ltd (NASDAQ:BLRX) were released by: Seekingalpha.com and their article: “BioLineRx: Expands Cancer Pipeline Significantly By Acquiring Novel Drug …” published on March 27, 2017 as well as Seekingalpha.com‘s news article titled: “BioLineRX: Update And Preview Of The Company’s Q4 And FY 2016 Financial …” with publication date: March 22, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.